Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)366.30
  • Today's Change-11.70 / -3.10%
  • Shares traded210.03k
  • 1 Year change-60.51%
  • Beta1.1007
Data delayed at least 15 minutes, as of Jul 11 2025 15:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

  • Revenue in DKK (TTM)55.69m
  • Net income in DKK-1.19bn
  • Incorporated1997
  • Employees385.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gubra A/S-100.00bn-100.00bn6.78bn236.00------------------------------------------------29.63--18.03------
Kuros Biosciences AG548.61m-27.18m8.73bn122.00--20.75--15.91-0.095-0.10912.351.360.96531.917.68561,141.40-4.78-10.85-5.94-12.2882.0484.11-4.95-31.801.69--0.0777--129.67101.5962.67--60.45--
BioArctic AB1.01bn602.22m9.12bn116.0018.088.4413.339.0010.2010.2017.1621.850.931----14,180,610.0055.34-2.8760.55-3.2297.6186.5959.44-12.41----0.0257---58.22-1.80-177.24--52.19--
Evotec SE5.88bn-1.54bn9.35bn4.77k--1.37--1.59-1.17-1.174.445.140.379520.844.29163,293.80-9.97-2.40-12.34-2.8713.6221.49-26.26-6.781.93-2.030.3442--1.9912.29-133.67--32.89--
Genus plc5.79bn-34.47m12.63bn3.44k--2.8437.212.18-0.0612-0.061210.167.820.6585--6.11195,289.30-0.62753.30-0.71993.87-----0.9534.981.33--0.365662.72-3.036.48-76.280.2551-2.682.93
Galapagos NV2.20bn-1.34bn12.81bn704.00--0.6249--5.81-2.72-2.574.4841.700.07050.77345.59419,666.20-4.28-2.04-4.74-2.2884.42---60.70-27.567.86--0.0039--14.99-20.8267.85--12.44--
BB BIOTECH AG554.27m-3.41bn13.83bn86.00--0.8762--24.95-7.78-7.781.2635.550.029--5.61804,244.20-17.82-1.24-19.26-1.3594.8097.19-615.24-39.47--0.07710.00--21,076.79-31.20136.74-35.45---11.94
Zealand Pharma A/S55.69m-1.19bn26.13bn385.00--3.12--469.23-17.30-17.300.811117.530.00880.54090.7554166,250.80-18.66-32.33-19.63-36.4993.3995.31-2,128.64-515.0325.07--0.0453---81.718.69-53.30---10.98--
BACHEM HOLDING AG4.85bn963.63m34.53bn2.21k35.763.1026.357.121.611.618.0718.550.33571.072.91274,245.106.678.267.619.4430.1631.5519.8720.061.33--0.000252.544.8414.057.5017.2956.917.21
Qiagen NV12.79bn598.02m66.54bn5.70k117.823.0436.385.200.34740.34747.8013.460.35292.115.64297,220.901.655.761.916.8864.0964.314.6816.852.83--0.2924--0.65655.32-75.51---9.03--
Eurofins Scientific SE51.87bn4.73bn82.37bn62.70k18.572.128.591.593.261.8135.7428.580.638438.445.00110,868.306.317.657.889.5322.3323.959.8811.411.097.950.401423.546.708.7822.8515.364.45--
Genmab A/S20.63bn7.24bn88.49bn2.64k12.232.5811.464.29112.77112.77321.18533.660.543411.544.387,690,525.0019.0717.7021.1319.0795.12--35.1035.775.32--0.0263--30.5731.1680.1028.5021.52--
Data as of Jul 11 2025. Currency figures normalised to Zealand Pharma A/S's reporting currency: Danish Krone DKK

Institutional shareholders

32.48%Per cent of shares held by top holders
HolderShares% Held
Capital International Ltd.as of 02 Jul 20254.36m6.15%
Fidelity Management & Research Co. LLCas of 31 May 20253.55m4.99%
J.O. Hambro Capital Management Ltd.as of 11 Jan 20243.13m4.40%
Polar Capital LLPas of 30 May 20252.42m3.41%
The Vanguard Group, Inc.as of 02 Jul 20252.40m3.37%
DWS Investments (UK) Ltd.as of 03 Jul 20251.80m2.53%
Capital Research & Management Co. (World Investors)as of 31 Mar 20251.48m2.09%
Schroder Investment Management Ltd.as of 31 May 20251.46m2.06%
Norges Bank Investment Managementas of 31 Dec 20241.26m1.78%
Handelsbanken Fonder ABas of 30 Jun 20251.20m1.69%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.